What Is Section 503A?

What Section 503A covers

Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act is the provision that defines traditional pharmacy compounding. In plain terms, it lets a licensed pharmacist (or physician) prepare a customized medication for a specific patient — for example, a liquid version of a drug for someone who cannot swallow a tablet, or a formulation without a dye a patient reacts to. The defining feature is that the preparation is patient-specific and generally made in response to a prescription for that individual.

Compounding under 503A is not the same as drug manufacturing. A manufacturer mass-produces a standardized, FDA-approved product; a 503A pharmacy makes a tailored preparation for one patient at a time. Because these preparations are not individually FDA-approved, 503A sets conditions a pharmacy must meet for the compounded product to be exempt from certain requirements — including a rule about which raw ingredients may be used.

Where 503A came from: the DQSA

The modern 503A framework comes from the Drug Quality and Security Act of 2013 (DQSA). Congress passed it after a 2012 fungal meningitis outbreak — traced to contaminated compounded injections from a single facility — killed dozens of people and exposed serious gaps in compounding oversight. The DQSA clarified FDA authority over compounding and split the landscape into two lanes: Section 503A for traditional, patient-specific pharmacy compounding, and [Section 503B](/what-is-503b) for larger "outsourcing facilities."

The heart of 503A is its bulk-substance rule. A pharmacy that compounds from a finished, FDA-approved drug is working with material the agency has already vetted. But when a pharmacy starts from raw active pharmaceutical ingredient — a bulk drug substance in powder form — none of that vetting exists. So the DQSA built a gatekeeping test to decide which bulk substances are acceptable at all.

The three 503A(b) sourcing paths

Under Section 503A(b), a pharmacy may compound from a bulk drug substance only if that substance satisfies at least one of three conditions. These are alternatives, not a checklist — clearing any single path is enough.

1. It is the subject of an applicable USP or NF monograph — an official United States Pharmacopeia / National Formulary quality standard defining identity, strength, and purity.
2. It is a component of an FDA-approved drug — an active ingredient in some product the FDA has already approved.
3. It appears on the FDA's 503A bulks list — a list the agency maintains of substances permitted in compounding even without a monograph or approved-drug link.

If a bulk substance meets none of these, the pharmacy is not permitted to compound with it. This is the exact test that decides whether a research peptide can enter the pharmacy channel — and it is why so many peptides are shut out. We walk through a worked example in can compounding pharmacies compound BPC-157?, where the peptide fails all three paths at once. For a look at where a peptide sits scientifically before this legal layer, see the BPC-157 research profile and how BPC-157 works.

Category 1 vs Category 2 on the bulks list

The third path — the 503A bulks list — has its own sorting system. When a substance is nominated for the list, the FDA places it, on an interim basis, into one of two buckets while it completes review. Category 1 means the substance may be used in compounding during that review. Category 2 means the FDA has identified significant safety concerns and takes the position that it should not be used in compounding while under review.

This distinction is where most research peptides run aground. From roughly 2020 through 2023–2024, the FDA sorted several peptides into Category 2, including BPC-157, TB-500 (thymosin beta-4), Ipamorelin, CJC-1295, and GHK-Cu. A Category 2 placement means the substance is technically on the list, but on the wrong side of it — so the third sourcing path is closed. The full mechanics are covered in the FDA 503A bulks list explained.

How 503A differs from 503B

It helps to place 503A next to its sibling. Section 503A is for traditional, patient-specific compounding by pharmacies — one preparation for one patient, generally against a prescription, under state pharmacy practice standards. [Section 503B](/what-is-503b) governs "outsourcing facilities" that can produce compounded preparations in larger batches without a patient-specific prescription, but must operate under federal current good manufacturing practice (cGMP) and use a separate, even stricter 503B bulks list.

In short, 503A is smaller-scale and prescription-driven; 503B is batch-scale and cGMP-governed. Neither can supply a Category 2 peptide, but they get there by different rules. Decisions about what belongs on either bulks list are informed by the Pharmacy Compounding Advisory Committee (PCAC), whose recommendations are advisory and non-binding.